For example, miR-596 suppresses the expression of survivin and enhances the sensitivity of osteosarcoma cells to the targeted molecular agent anlotinib (25), and treatment with a PI3K inhibitor was found to impair tumor progression and enhance sensitivity to anlotinib in anlotinib-resistant osteosarcoma (26). This evidence concerns the gene BIRC5 and neoplasm.